Gross Profit Analysis: Comparing AbbVie Inc. and Bausch Health Companies Inc.

AbbVie vs. Bausch Health: A Decade of Gross Profit Trends

__timestampAbbVie Inc.Bausch Health Companies Inc.
Wednesday, January 1, 2014155340000006008900000
Thursday, January 1, 2015183590000007853800000
Friday, January 1, 2016198050000007063000000
Sunday, January 1, 2017211760000006176000000
Monday, January 1, 2018250350000006029000000
Tuesday, January 1, 2019258270000006251000000
Wednesday, January 1, 2020304170000005778000000
Friday, January 1, 2021387510000006040000000
Saturday, January 1, 2022406400000005760000000
Sunday, January 1, 2023339030000006198000000
Monday, January 1, 20240
Loading chart...

Cracking the code

Gross Profit Trends: AbbVie Inc. vs. Bausch Health Companies Inc.

In the ever-evolving pharmaceutical industry, understanding financial performance is crucial. This analysis highlights the gross profit trends of two major players: AbbVie Inc. and Bausch Health Companies Inc., from 2014 to 2023. Over this period, AbbVie Inc. has demonstrated a robust growth trajectory, with its gross profit increasing by approximately 118%, peaking in 2022. In contrast, Bausch Health Companies Inc. has experienced a more modest growth of around 3% over the same period. Notably, AbbVie's gross profit in 2022 was nearly seven times that of Bausch Health, underscoring its dominant market position. The data reveals a significant dip for AbbVie in 2023, yet it remains substantially ahead. These insights provide a window into the competitive landscape of the pharmaceutical sector, where strategic financial management is key to sustaining growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025